Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies

Neuroscience Letters

Volumn 569, Issue , 2014, Pages 68-73

  Kasanuki, Koji ^a,b   Iseki, Eizo ^a,b   Kondo, Daizo ^a,c   Fujishiro, Hiroshige ^a   Minegishi, Michiko ^a   Sato, Kiyoshi ^a   Katsuse, Omi ^c   Hino, Hiroaki ^c   Kosaka, Kenji ^c   Arai, Heii ^b  

^a JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Dementia with Lewy bodies; Hypocretin; Narcolepsy; Neuropathology; Tau; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; OREXIN; TAU PROTEIN; AMYLOID BETA PROTEIN; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ADOLESCENT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEWY BODY; LOCUS CERULEUS; MALE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BRAIN; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; NERVE CELL; NERVE FIBER; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AXONS; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEURONS; NEUROPEPTIDES; TAU PROTEINS;

EID: 84898814336     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.03.020     Document Type: Article

References (24)

1. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurol. Sci. 1998, 18:9996-10015.
2. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
3. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
4. Baumann C.R., Bassetti C.L. Hypocretins (orexins) and sleep-wake disorders. Lancet Neurol. 2005, 10:673-682.
5. Ondo W.G., Dat Vuong K., Khan H., Atassi F., Kwak C., Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001, 57:1392-1396.
6. Razmy A., Lang A.E., Shapiro C.M. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch. Neurol. 2004, 61:97-102.
7. Arnulf I., Konofal E., Merino-Andreu M., Houeto J.L., Mesnage V., Welter M.L., Lacomblez L., Golmard J.L., Derenne J.P., Agid Y. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002, 58:1019-1024.
8. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
9. Fronczek R., Overeem S., Lee S.Y.Y., Hegeman I.M., van Pelt J., van Duinen S.G., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
10. Fronczek, van Geest S., Frölich M., Overeem S., Roelandse F.W., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol. Aging 2012, 33:1642-1650.
11. Baumann C.R., Bassetti C.L., Valko P.O., Haybaeck J., Keller M., Clark E., Stocker R., Tolnay M., Scammell T.E. Loss of hypocretin (orexin) neurons with traumatic brain injury. Ann. Neurol. 2009, 66:555-559.
12. Lessig S., Ubhi K., Galasko D., Adame A., Pham E., Remidios K., Chang M., Hansen L.A., Masliah E. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. Neuroreport 2010, 21:756-760.
13. Kasanuki K., Iseki E., Fujishiro H., Yamamoto R., Higashi S., Minegishi M., Togo T., Katsuse O., Uchikado H., Furukawa Y., Hino H., Kosaka K., Sato K., Arai H. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J. Neurosci. 2012, 314:111-119.
14. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa T., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Consortium on DLB, diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
15. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
16. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
17. Saito Y., Kawashima A., Ruberu N.N., Fujiwara H., Koyama S., Sawabe M., Arai T., Nagura H., Yamanouchi H., Hasegawa M., Iwatsubo T., Murayama S. Accumulation of phosphorylated alpha-synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 2003, 62:644-654.
18. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
19. Thannickal T.C., Siegel J.M., Nienhuis R., Moore R.Y. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol. 2003, 13:340-351.
20. Frucht S., Rogers J.D., Greene P.E., Gordon M.F., Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908-1910.
21. Wennström M., Londos E., Minthon L., Nielsen H.M. Altered CSF orexin and α-synuclein levels in dementia patients. J. Alzheimers Dis. 2012, 29:125-132.
22. Grossberg A.J., Zhu X., Leinninger G.M., Levasseur P.R., Braun T.P., Myers M.G., Marks D.L. Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J. Neurosci. 2011, 31:11376-11386.
23. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
24. Tansey M., Goldberg M. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518.